Although TP53 mutations are predominant in high-grade serous carcinoma and are the most common pathological type of epithelial ovarian cancer, KRAS mutations are more common in low-grade serous carcinoma and endometriosis-driven pathological types (clear cell or endometrioid carcinoma). This evidence concerns the gene KRAS and endometrioid adenocarcinoma.